Characterization of GAB1 expression over the menstrual cycle in women with and without polycystic ovarian syndrome provides a new insight into its pathophysiology

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages E2162-E2168

  Roemer, K L ^a   Young, S L ^a   Savaris, R F ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DOCKING PROTEIN; ESTRADIOL; INSULIN RECEPTOR; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN GAB1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; GAB1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; ARTICLE; CASE CONTROL STUDY; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CELL; EXPERIMENTAL STUDY; FEMALE; GAB1 GENE; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TERTIARY HEALTH CARE; WESTERN BLOTTING; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DOWN-REGULATION; ENDOMETRIUM; EPITHELIAL CELLS; ESTRADIOL; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MENSTRUAL CYCLE; PHOSPHORYLATION; POLYCYSTIC OVARY SYNDROME; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84910011543     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2128     Document Type: Article

References (25)

1. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33: 981-1030.
2. Fornes R, Ormazabal P, Rosas C, et al. Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia. Mol Med. 2010;16: 129-136.
3. Ormazabal P, Romero C, Gabler F, Quest AF, Vega M. Decreased phosphorylation of Y(1)(4)caveolin-1 in endometrial tissue of polycystic ovary syndrome patients may be related with an insulin resistant state in this tissue. Horm Metab Res. 2013;45: 291-296.
4. Savaris RF, Groll JM, Young SL, et al. Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citratetreated and artificial menstrual cycles. J Clin Endocrinol Metab. 2011;96: 1737-1746.
5. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulinreceptor signalling. Nature. 1996;379: 560-564.
6. Wohrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal. 2009;7: 22.
7. WhiteMF.The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem. 1998;182: 3-11.
8. Gu H, Neel BG. The "Gab" in signal transduction. Trends Cell Biol. 2003;13: 122-130.
9. Plante BJ, Lessey BA, Taylor RN, et al. G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium. Reprod Sci. 2012;19: 684-693.
10. Lathi RB, Hess AP, Tulac S, Nayak NR, Conti M, Giudice LC. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. J Clin Endocrinol Metab. 2005;90: 1599-1606.
11. Pohnke Y, Schneider-Merck T, Fahnenstich J, et al. Wild-type p53 protein is up-regulated upon cyclic adenosine monophosphate-induced differentiation of human endometrial stromal cells. J Clin Endocrinol Metab. 2004;89: 5233-5244.
12. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19: 41-47.
13. Usadi RS, Groll JM, Lessey BA, et al. Endometrial development and function in experimentally induced luteal phase deficiency. J Clin Endocrinol Metab. 2008;93: 4058-4064.
14. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3: 1101-1108.
15. Burry RW. Controls for immunocytochemistry: an update. J Histochem Cytochem. 2011;59: 6-12.
16. Fuhrich DG, Lessey BA, Savaris RE. Comparison of HSCORE assessment of endometrial β3 integrin subunit expression with digital HSCORE using computerized image analysis (ImageJ). Anal Quant Cytol Histol. 2013;35: 210-216.
17. Jekel JF, Elmore JG, Katz DL. Sample size, randomization, and probability theory. In: Jekel JF, Elmore JG, Katz DL, eds. Epidemiology, Biostatistics, Preventive Medicine. Philadelphia: W. B. Saunders Co; 1996: 160-171.
18. Kahn CR. The molecular mechanism of insulin action. Annu Rev Med. 1985;36: 429-451.
19. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15: 6529-6540.
20. Hayakawa-Yano Y, Nishida K, Fukami S, et al. Epidermal growth factor signaling mediated by grb2 associated binder1 is required for the spatiotemporally regulated proliferation of olig2-expressing progenitors in the embryonic spinal cord. Stem Cells. 2007;25: 1410-1422.
21. Lehr S, Kotzka J, Avci H, et al. Identification of major ERK-related phosphorylation sites in Gab1. Biochemistry. 2004;43: 12133-12140.
22. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12: 324-332.
23. Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol. 2005;19: 379-390.
24. Giudice LC. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab. 2006; 20: 235-244.
25. Bard-Chapeau EA, Hevener AL, Long S, Zhang EE, Olefsky JM, Feng GS. Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action. Nat Med. 2005;11: 567-571.